Colchicine - Hikma Pharmaceuticals

Drug Profile

Colchicine - Hikma Pharmaceuticals

Alternative Names: Mitigare

Latest Information Update: 26 Mar 2015

Price : $50

At a glance

  • Originator Hikma Pharmaceuticals
  • Class Antigouts; Antineoplastics; Colchicum alkaloids; Small molecules
  • Mechanism of Action Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Gout

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 09 Jan 2015 Re-launched for Gout (Prevention, In adults) in USA (PO)
  • 30 Sep 2014 Registered for Gout (Prevention, In adults) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top